Westminster, Colorado-based Highridge — the spine company sold by ZimVie to H.I.G Capital in 2024, two years after ZimVie spun out of Zimmer Biomet — also announced the successful completion of initial surgeries at multiple disc replacement centers nationwide.
As part of the launch, Highridge partnered with leading arthroplasty surgeons to support early adoption of activL. It says the motion preservation solution was designed to restore function and maintain mobility for patients with lumbar disc degeneration.
According to Highridge, early adopters of the activL lumbar disc expressed their confidence in the technology and its clinical performance. The company says its latest launch marks a significant milestone in the expansion of its portfolio. It said the rollout reinforces its mission as well.
Highridge inked a licensing deal for the activL lumbar disc system with B. Braun in July 2025. Aesculap AG — now owned by Germany-based B. Braun — trademarked the activL name in 2007. It won FDA premarket approval (PMA) for the activL Artificial Disc in 2015. The company then picked up 510(k) clearance for activL Next Generation Instrumentation in 2023.
“We are excited to initiate the limited launch of the activL lumbar disc and expand access to this important treatment option for surgeons and their patients,” said Rebecca Whitney, CEO of Highridge Medical. “The strong early adoption and positive feedback from leading surgeons validate our strategy to broaden our motion preservation portfolio beyond our market-leading Mobi-C cervical disc. We are committed to delivering exceptional service and clinical support as we continue to scale availability.”
